colorectal cancer Archives -

Disappointment as Lynparza fails colorectal cancer test

Phil Taylor AstraZeneca, colorectal cancer, Lynparza, Merck & Co, Oncology, PARP inhibitor 0 Comment

AstraZeneca and Merck’s PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and

Disappointment as Lynparza fails colorectal cancer test

https://pharmaphorum.com/news/disappointment-as-lynparza-fails-colorectal-cancer-test/

Gastrointestinal Cancer Drug Development Summit Register Free

Events/ Events/ Oncology

FREE – Gastrointestinal Cancer Drug Development Digital Summit

Serena Pickford Phimmai colorectal cancer, gastrointestinal cancer, GI Cancer, Oncology, precision oncology 0 Comment

FREE – Gastrointestinal Cancer Drug Development Summit

FREE – Gastrointestinal Cancer Drug Development Digital Summit

https://pharmaphorum.com/events/free-gastrointestinal-cancer-drug-development-digital-summit/

News/ News/ Oncology

ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRC

Phil Taylor Amgen, Boehringer Ingelheim, colorectal cancer, ESMO, KRAS, Lumakras, Oncology, Vectibix 0 Comment

Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting

ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRC

https://pharmaphorum.com/news/esmo21-first-combo-data-with-amgens-lumakras-hit-the-mark-in-crc/

Medtronic_GI_Genius_intelligent_endoscopy_module

Digital/ News/ News

AI device cleared by FDA to spot lesions during colonoscopy

Phil Taylor artificial intelligence, colorectal cancer, Cosmo Pharma, digital, digital health, Mallinckrodt, screening 0 Comment

The FDA has approved the first artificial intelligence-powered device that can be used to help identify colorectal lesions

AI device cleared by FDA to spot lesions during colonoscopy

https://pharmaphorum.com/news/ai-device-cleared-by-fda-to-spot-lesions-during-colonoscopy/

Market Access/ News/ News

NICE says yes to Braftovi combination for colorectal cancer

Phil Taylor Braftovi, colorectal cancer, NHS, NICE, Pierre Fabre 0 Comment

Two months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer (mCRC), NICE has

NICE says yes to Braftovi combination for colorectal cancer

https://pharmaphorum.com/news/nice-says-yes-to-braftovi-combination-for-colorectal-cancer/

News/ News/ Oncology

Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review

Richard Staines colorectal cancer, fda, Keytruda, Merck & Co, regulation 0 Comment

It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal

Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review

https://pharmaphorum.com/news/merck-cos-keytruda-gets-new-colorectal-cancer-use-after-month-long-fda-review/

News/ News/ News/ Oncology/ R&D

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

Phil Taylor ASCO 2020, AstraZeneca, colorectal cancer, Daiichi Sankyo, her2, lung cancer, stomach cancer 0 Comment

With an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

https://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/

News/ News/ Oncology/ Top stories

Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancer

Richard Staines cancer, colorectal cancer, immunotherapy, Keytruda, Merck & Co, Merck KGaA, Oncology, Roche 0 Comment

Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations,

Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancer

https://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/

News/ News/ Oncology

FDA approves Pfizer/Merck KGaA combo in advanced colorectal cancer

Richard Staines cancer, colorectal cancer, Merck KGaA, Pfizer, R&D 0 Comment

The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated

FDA approves Pfizer/Merck KGaA combo in advanced colorectal cancer

https://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaa-combo-in-advanced-colorectal-cancer/

Trending

colorectal cancer

Login